缓解COPD系统性皮质类固醇风险:呼吁提前启动三重疗法
1Hospital de G Baigorria, Universidad Nacional de Rosario, Argentina.
Pulmonary pharmacology & therapeutics
|June 5, 2025
概括
对于患有慢性阻塞性肺病 (COPD) 患病患有严重恶化风险的患者,早期的三重疗法 (长效β-激动剂,长效肌抗体和吸入性皮质类固醇) 提供了显著的益处. 尽量减少全身皮质类固醇 (SCS) 的使用,可以保护它们免受严重事件的影响,并减少不良后果.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 目前的GOLD指南建议在高风险的COPD患者中进行初始双重治疗 (LABA/LAMA),并稍后增加ICS.
- 系统性皮质类固醇 (SCS) 用于严重恶化,但随着累积暴露而带来重大风险.
- 高风险的COPD患者可能具有有限的"SCS信用",在恶化后增加并发症风险.
研究的目的:
- 评估在高风险,有症状的COPD患者中早期启动三重疗法的益处.
- 倡导在COPD管理中尽量减少全身皮质类固醇 (SCS) 暴露.
- 促进精准医学指导早期三重疗法决策.
主要方法:
- 审查当前的COPD治疗指南和相关的临床研究.
- 对累积系统性皮质类固醇 (SCS) 暴露对不良结果的影响分析.
- 早期三重疗法与高风险COPD人群的标准护理的比较.
主要成果:
- 在高风险,有症状的COPD患者中,早期启动三重疗法 (LABA/LAMA/ICS) 显示出显著的益处.
- 与标准护理方法相比,三重疗法改善了生活质量.
- 尽量减少SCS使用至关重要,类似于喘管理,以预防内分泌疾病和肺炎等不良事件.
结论:
- 在高风险,有症状的COPD患者中,应考虑早期的三重治疗,以改善结果和生活质量.
- 需要精准医学方法来指导早期使用三重疗法.
- 减少累积的SCS暴露对于长期的COPD患者健康至关重要,并为关键事件保护SCS.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
331
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
331
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
399
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
399
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K
01:19Antiasthma Drugs: Leukotriene Modifiers
505
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
505
01:20Asthma: Pathogenesis and Management
623
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
623
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K